Jeremy B. Hayden Sells 6,922 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 6,922 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $2.78, for a total value of $19,243.16. Following the transaction, the insider now owns 145,091 shares in the company, valued at $403,352.98. This trade represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sight Sciences Price Performance

Shares of SGHT opened at $2.88 on Thursday. The firm has a market capitalization of $146.19 million, a price-to-earnings ratio of -2.82 and a beta of 2.57. The stock’s fifty day moving average is $3.57 and its 200-day moving average is $5.33. Sight Sciences, Inc. has a one year low of $2.67 and a one year high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $20.16 million during the quarter, compared to analyst estimates of $20.41 million. Equities analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Sight Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGHT. KCK LTD. bought a new stake in shares of Sight Sciences in the 4th quarter worth $15,925,000. Long Focus Capital Management LLC raised its position in Sight Sciences by 86.9% in the second quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after acquiring an additional 260,594 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in Sight Sciences in the 2nd quarter valued at about $1,234,000. Millrace Asset Group Inc. bought a new position in shares of Sight Sciences during the 3rd quarter valued at about $874,000. Finally, State Street Corp grew its stake in shares of Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after purchasing an additional 95,843 shares during the last quarter. 55.51% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SGHT shares. Lake Street Capital reduced their price target on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Wednesday, January 15th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Tuesday, January 14th. UBS Group assumed coverage on Sight Sciences in a research note on Friday, December 6th. They issued a “buy” rating and a $5.50 target price for the company. Piper Sandler reiterated a “neutral” rating and set a $5.50 price target (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Finally, Morgan Stanley reduced their price objective on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, November 11th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Sight Sciences has an average rating of “Hold” and a consensus price target of $4.72.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.